BIO PRODUCTS
SunBio’s technology and PEG products have been instrumental in the success of several marketed biopharmaceuticals and medical devices. A summary of both launched and pipeline products is provided in the table below.
| Product/Candidate | Status | Literature | |
|---|---|---|---|
| Biopharma | Pelgraz (a PEG-filgrastim biosimilar) | Approved and marketed in EU (2018) Approved and marketed in Australia (2022) Approved and marketed in Mexico (2022) |
• Efectiveness and safety of pegylated flgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany
• Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim (PELGRAZ)
|
| Lapelga (a PEG-filgrastim biosimilar) | Approved and marketed in Canada (2018) |
• Primary Prophylaxis Lapelga® in Early Breast Cancer:A Real-World Experience
|
|
| SBX (a blood substitute) | Preclinical | - | |
| X-PEG-PAL (a novel PEG-phenylalanine ammonia lyase to treat phenylketonuria) | Preclinical | - | |
| X-PEG-uricase (a PEG-uricase to treat gout) | Preclinical | - | |
| LNP (a novel mRNA vaccine delivery) | Preclinical | - | |
| Medical Device | MucoPEG (xerostomia treatment) | FDA approved (2019) Filing for approval in Japan (2025) Filing for approval in a region in China (2025) |
Clinical Evaluation of a Polyethylene Glycol Derivative Rinse for Xerostomia
|
| SynoGel (a stem cell delivery device) | Preclinical | - | |
| PEG Products | Manufacture and Sales | Marketed (1998) | - |